These open your broker's own site — any real trade happens there, not here. Not financial advice.
ASND
Ascendis Pharma A/S
$256.82
Quote as of 11/6/2026, 4:00:01 PM ET
ASND
Ascendis Pharma A/S
$256.82
Thesis
Ascendis Pharma A/S (ASND): momentum is building as the news centers on "Ascendis Pharma's TransCon CNP Gets EU Orphan-Drug Designation Recommendation for Achondroplasia" (MT Newswires).
- Up 15.3% over the past month
- Sitting 73% of the way up its 52-week range
- Latest 6-K filed 2026-11-06
Educational research only — not financial advice. Lean describes past price action, not a forecast.
Historical price
Daily closing prices · USD · Yahoo Finance. The latest session may be incomplete. Period change compares the first and last displayed closes; it is not total return or options profit.
Key performance ranges
- Day range
- $251.02 – $258.46
- 52-week range
- $188.07 – $282.15
- 1Y observed range
- $188.07 – $282.15
- Session volume
- 883,846
- Displayed sessions
- 252
- Currency
- USD
ASND news
MT Newswires · 11/6/2026
Ascendis Pharma's TransCon CNP Gets EU Orphan-Drug Designation Recommendation for Achondroplasia
Read article
GlobeNewswire · 11/6/2026
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
Read article
GlobeNewswire · 11/5/2026
Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
Read article
GlobeNewswire · 11/2/2026